{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:14:51Z","timestamp":1792790091015,"version":"4.5.0"},"reference-count":43,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Our study retrospectively investigated the therapeutic effects of SGLT2 inhibitors on multiple outcomes in patients with Type 2 Diabetes, capitalizing on the agent\u2019s proven benefits in glycemic, cardiovascular, and renal systems. Methods: This retrospective cohort study investigated a total of 200 patients with T2DM, 100 SGLT2I-treated and 100 treated without SGLT2Is. Clinical data were retrieved from the electronic health record system of the hospital. Patients were followed for more than 6 months to assess the effects of SGLT2Is on metabolic, biochemical, and renal parameters. Results: In the SGLT2I-treated cohort, a higher prevalence of males, non-geriatrics, and comorbidities such as HF and ASCVD was observed with greater use of concomitant medications (beta-blockers, antithrombotics, antilipidemics). SGLT2I treatments show a greater reduction in FBG (control: \u22126.3 mg\/dL vs. treatment: \u221224.2 mg\/dL; p \u2264 0.05), HbA1c (control: \u22120.093% vs. treatment: \u22120.76%; p \u2264 0.001), weight (control: \u22120.6 kg vs. treatment: \u22123.6 kg; p \u2264 0.001), SBP (control: 5.8 mmHg vs. treatment: \u22129.2 mmHg; p \u2264 0.001), and DBP (control: 2.2 mmHg vs. treatment: \u22124.7 mmHg; p \u2264 0.05) compared to the control group. The analysis of the mean change in eGFR showed no statistically significant difference in both groups. The SGLT2I\u2019s safety profile was favorable, with no difference in adverse events and no cases of euglycemic ketoacidosis or Fournier\u2019s gangrene. Conclusions: In this study, SGLT2Is demonstrated strong clinical efficacy in improving multiple cardiometabolic parameters without compromising patient safety in short-term follow-up. Large-scale and long-term real-world studies are needed to monitor the long-term safety profile, characterize the incidence of rare adverse events in general clinical practice, and validate results from this study.<\/jats:p>","DOI":"10.3390\/jcm15072550","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T11:12:25Z","timestamp":1774609945000},"page":"2550","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of SGLT2 Inhibitors on Multiple Cardiometabolic Risk Factors: A Retrospective Cohort Study"],"prefix":"10.3390","volume":"15","author":[{"given":"Hilal","family":"I\u015f\u0131k","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, \u0130zmir Atat\u00fcrk Training and Research Hospital, 35360 Izmir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9796-111X","authenticated-orcid":false,"given":"Kader K\u00fcbra","family":"Demird\u00f6\u011fen","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Faculty of Pharmacy, Hacettepe University, 06230 Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teoman","family":"\u00c7ak\u0131r","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism Disorders, \u0130zmir Atat\u00fcrk Training and Research Hospital, 35150 Izmir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u015eevki","family":"\u00c7etinkalp","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism Disorders, Faculty of Medicine, Ege University, 35100 Izmir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeliha","family":"Kerry","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Faculty of Pharmacy, Ege University, 35100 Izmir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9704-9737","authenticated-orcid":false,"given":"Mehmet Zuhuri","family":"Arun","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Faculty of Pharmacy, Ege University, 35100 Izmir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"109119","DOI":"10.1016\/j.diabres.2021.109119","article-title":"IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045","volume":"183","author":"Sun","year":"2022","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.2522\/ptj.20080020","article-title":"Epidemiology of diabetes and diabetes-related complications","volume":"88","author":"Deshpande","year":"2008","journal-title":"Phys. Ther."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/PL00002934","article-title":"Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes","volume":"44","author":"Morrish","year":"2001","journal-title":"Diabetologia"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1464-5491.2009.02894.x","article-title":"Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: Therapeutic implications","volume":"27","author":"Gerich","year":"2010","journal-title":"Diabetes Medicat."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"4","DOI":"10.2337\/diaclin.32.1.4","article-title":"SGLT-2 Inhibitors: A New Mechanism for Glycemic Control","volume":"32","author":"Chao","year":"2014","journal-title":"Clin. Diabetes"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/dom.12670","article-title":"Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: Systematic review and network meta-analysis","volume":"18","author":"Zaccardi","year":"2016","journal-title":"Diabetes Obes. Metab."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.jash.2014.02.003","article-title":"Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors","volume":"8","author":"Oliva","year":"2014","journal-title":"J. Am. Soc. Hypertens."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"468","DOI":"10.2337\/dc19-1476","article-title":"Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE-TIMI 58 Study","volume":"43","author":"Cahn","year":"2020","journal-title":"Diabetes Care"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"356","DOI":"10.2337\/dc17-1096","article-title":"How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial","volume":"41","author":"Inzucchi","year":"2018","journal-title":"Diabetes Care"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure","volume":"383","author":"Packer","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in Patients with Chronic Kidney Disease","volume":"383","author":"Greene","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","article-title":"2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes: Developed by the task force on the management of cardiovascular disease in patients with diabetes of the European Society of Cardiology (ESC)","volume":"44","author":"Marx","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"ADA (2024). 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes\u20142025. Diabetes Care, 48, S27\u2013S49.","DOI":"10.2337\/dc25-S002"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"KDIGO (2024). KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int., 105, 117\u2013314.","DOI":"10.1016\/j.kint.2023.09.002"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.diabet.2020.01.002","article-title":"Reduction in HbA1c with SGLT2 inhibitors vs. DPP-4 inhibitors as add-ons to metformin monotherapy according to baseline HbA1c: A systematic review of randomized controlled trials","volume":"46","author":"Scheen","year":"2020","journal-title":"Diabetes Metab."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"599","DOI":"10.4330\/wjc.v14.i11.599","article-title":"Potential for sodium-glucose cotransporter-2 inhibitors in the management of metabolic syndrome: A systematic review and meta-analysis","volume":"14","author":"Olagunju","year":"2022","journal-title":"World J. Cardiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"A58","DOI":"10.1186\/1758-5996-7-S1-A58","article-title":"Efficacy of SGLT2 inhibitors in glycemic control, weight loss and blood pressure reduction: A systematic review and meta-analysis","volume":"7","author":"Pinto","year":"2015","journal-title":"Diabetol. Metab. Syndr."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1001\/jama.2024.27402","article-title":"Age and Sex Differences in Efficacy of Treatments for Type 2 Diabetes: A Network Meta-Analysis","volume":"333","author":"Hanlon","year":"2025","journal-title":"JAMA"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/dom.12503","article-title":"Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: A 78-week randomized, double-blind, placebo-controlled trial","volume":"17","author":"Rosenstock","year":"2015","journal-title":"Diabetes Obes. Metab."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"405","DOI":"10.7326\/0003-4819-156-6-201203200-00003","article-title":"Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: A randomized trial","volume":"156","author":"Wilding","year":"2012","journal-title":"Ann. Intern. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"262","DOI":"10.7326\/0003-4819-159-4-201308200-00007","article-title":"Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: A systematic review and meta-analysis","volume":"159","author":"Vasilakou","year":"2013","journal-title":"Ann. Intern. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e015323","DOI":"10.1161\/JAHA.119.015323","article-title":"Effect of Hemoglobin A1c Reduction or Weight Reduction on Blood Pressure in Glucagon-Like Peptide-1 Receptor Agonist and Sodium-Glucose Cotransporter-2 Inhibitor Treatment in Type 2 Diabetes Mellitus: A Meta-Analysis","volume":"9","author":"Hu","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1007\/s00592-023-02154-4","article-title":"Blood pressure-lowering effects of SGLT2 inhibitors and GLP-1 receptor agonists for preventing of cardiovascular events and death in type 2 diabetes: A systematic review and meta-analysis","volume":"60","author":"Diallo","year":"2023","journal-title":"Acta Diabetol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"ADA (2022). 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2022. Diabetes Care, 45, 125\u2013143.","DOI":"10.2337\/dc22-S009"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"117236","DOI":"10.1016\/j.atherosclerosis.2023.117236","article-title":"SGLT2-inhibition increases total, LDL, and HDL cholesterol and lowers triglycerides: Meta-analyses of 60 randomized trials, overall and by dose, ethnicity, and drug type","volume":"394","author":"Bechmann","year":"2024","journal-title":"Atherosclerosis"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ejim.2008.06.011","article-title":"Gender differences in the lipid profile of dyslipidemic subjects","volume":"20","author":"Kolovou","year":"2009","journal-title":"Eur. J. Intern. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1016\/j.jacc.2018.01.085","article-title":"SGLT-2 Inhibitors and Cardiovascular Risk: An Analysis of CVD-REAL","volume":"71","author":"Cavender","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1111\/dom.13424","article-title":"Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real-world meta-analysis of 4 observational databases (OBSERVE-4D)","volume":"20","author":"Ryan","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1007\/s00125-024-06126-3","article-title":"Effectiveness and safety of empagliflozin: Final results from the EMPRISE study","volume":"67","author":"Htoo","year":"2024","journal-title":"Diabetologia"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1111\/jce.16344","article-title":"SGLT2i effect on atrial fibrillation: A network meta-analysis of randomized controlled trials","volume":"35","author":"Mariani","year":"2024","journal-title":"J. Cardiovasc. Electrophysiol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1159\/000546838","article-title":"SGLT2 Inhibitors May Increase Creatinine Clearance: Data Mining Utilizing the FDA Adverse Event Report System Database and Pharmacokinetic Study with Rats","volume":"110","author":"Uwai","year":"2025","journal-title":"Pharmacology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"119","DOI":"10.4103\/ijp.ijp_342_21","article-title":"Impact of sodium-glucose co-transporter 2 inhibitors on renal outcomes in patients of diabetes mellitus: A meta-analysis of landmark renal and cardiovascular outcome trials","volume":"55","author":"Bose","year":"2023","journal-title":"Indian J. Pharmacol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/1753-0407.13348","article-title":"Effect of sodium-glucose cotransporter 2 inhibitors on the rate of decline in kidney function: A systematic review and meta-analysis","volume":"15","author":"Duo","year":"2023","journal-title":"J. Diabetes"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Mascolo, A., Di Napoli, R., Balzano, N., Cappetta, D., Urbanek, K., De Angelis, A., Scisciola, L., Di Meo, I., Sullo, M.G., and Rafaniello, C. (2022). Safety profile of sodium glucose co-transporter 2 (SGLT2) inhibitors: A brief summary. Front. Cardiovasc. Med., 9.","DOI":"10.3389\/fcvm.2022.1010693"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s10354-025-01108-5","article-title":"Treatment outcomes and safety profile of SGLT2 inhibitors versus GLP-1 agonists in type 2 diabetes mellitus","volume":"176","author":"Alam","year":"2026","journal-title":"Wien. Med. Wochenschr."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00228-026-04023-9","article-title":"Beyond safety: Adverse events and unanticipated advantages of SGLT2 inhibitors","volume":"82","author":"Falsetti","year":"2026","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"102606","DOI":"10.1016\/j.dsx.2022.102606","article-title":"Influence of sodium-glucose Co-transporter 2 inhibitors on clinical and biochemical markers of dehydration during the Holy Ramadan","volume":"16","author":"Gameil","year":"2022","journal-title":"Diabetes Metab. Syndr."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Ciuca-Pan\u0103, M.-A., Boulmpou, A., Ileri, C., Manzi, G., Golino, M., Ostojic, M., Galimzhanov, A., Busnatu, S., Mega, S., and Perone, F. (2025). Chronic Heart Failure and Coronary Artery Disease: Pharmacological Treatment and Cardiac Rehabilitation. Medicina, 61.","DOI":"10.3390\/medicina61020211"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/7\/2550\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T11:21:26Z","timestamp":1774610486000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/7\/2550"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,27]]},"references-count":43,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["jcm15072550"],"URL":"https:\/\/doi.org\/10.3390\/jcm15072550","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,27]]}}}